AU2005324199A1 - Taurine synthesis, production and utility as a medicine - Google Patents
Taurine synthesis, production and utility as a medicine Download PDFInfo
- Publication number
- AU2005324199A1 AU2005324199A1 AU2005324199A AU2005324199A AU2005324199A1 AU 2005324199 A1 AU2005324199 A1 AU 2005324199A1 AU 2005324199 A AU2005324199 A AU 2005324199A AU 2005324199 A AU2005324199 A AU 2005324199A AU 2005324199 A1 AU2005324199 A1 AU 2005324199A1
- Authority
- AU
- Australia
- Prior art keywords
- effective
- concentrations
- prevention
- combinations
- controlling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title claims description 33
- 229960003080 taurine Drugs 0.000 title claims description 16
- 230000015572 biosynthetic process Effects 0.000 title description 4
- 239000003814 drug Substances 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 230000002265 prevention Effects 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 5
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 206010008635 Cholestasis Diseases 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 230000007870 cholestasis Effects 0.000 claims description 3
- 231100000359 cholestasis Toxicity 0.000 claims description 3
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 201000001883 cholelithiasis Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 3
- 239000004380 Cholic acid Substances 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 229960002471 cholic acid Drugs 0.000 description 3
- 235000019416 cholic acid Nutrition 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000002245 gallstone dissolution Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
WO 2006/072259 PCT/EG2005/000044 1 Taurine synthesis, production and utility as a medicine Technical Field: 1. Medicine Background Art: The quantitatively most important pathway for the excretion of cholesterol in mammals is the formation of bile salts (the conjugate bases of bile acids). The major bile salts are synthesized and secreted by as glycine or taurine conjugates. Disclosure of Invention: Taurine is a degradation product of cysteine. Taurine (2-aminoethyl sulphonic acid) is a component of bile. It combines with cholic acid to form taurocholic acid. Cholic acid is the metabolic fate of cholesterol. The formation of cholic acid involves a pathway involving several hydroxylations and oxidation reactions. All water soluble vitamins participate in these reactions. Taurine lowers cholesterol, and this action is potentiated by the presence of water soluble vitamins. Taurine is effective in lowering hypercholesterolaemia, hypertriglyceridaemia and all lipid associated disorders as in cholestasis or nephrotic syndrome, etc.. also it is effective in any type of familial or idiopathic or acquired lipid disorder. Taurine is cardioprotective. Taurine is also effective in gall stone dissolution. Taurine is safe, and effective in normalizing high cholesterol, low density lipoproteins, or very low density lipoproteins. Taurine is also essential for stabilizing brain cells against changes in blood osmolality, and in conversion of serotonin to endorphins. It is effective in depression, migraine, headache, Alzheimer disease, and in psychiatric and neurological diseases.
WO 2006/072259 PCT/EG2005/000044 2 The Novel Idea: To control: blood levels of lipids, lipoproteins, cholesterol, and hypercholestrolaemia associated diseases, psychiatric and neurological diseases and in gall stone dissolution, the following singly or combined are effective: a. Taurine b. Cysteine and/or acetyl cysteine, c. All water soluble vitamins. Detailed Description of the Requested Patent: a. Taurine manufactured by all known ways as sulphonation of ethyl alcohol followed by substitution reaction at C2 or recombinant DNA technology to produce 2 aminoethyl sulphonic acid or any possible way, or by the use probiotics to promote the use of intestinal bacterial flora to reclaim taurine from the previously liver formed taurocholic acid and taurochenodexoycholic acid etc.... b. Acetyl cysteine is manufactured by all known ways. c. Water soluble vitamins are manufactured by all known ways. Where: i. All " a" "b" and "c" are effective if given as "a", or "b" or "c" or as "a+b", or "a+c"; or "b+c" or, "a+ b+ c". ii. All " a" "b" and "c" are effective if given as 'a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" when provided in oral or parenteral, or topical preparations. iii. All and any composition and any and all concentrations of ''a'', or "b" or "'c"5 or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" are effective. iv. Taurine used comes in its acid form or acid salt or alkali salt or in any of its compounds, or forms.
WO 2006/072259 PCT/EG2005/000044 3 v. The "a", or "b" or 4c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling asthersclerosis and cardiac diseases. vi. The "a", or "b" or "c"' or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling all hypercholestrolaemias, hypertriglycerdaemias, and all and any lipid and lipoprotein disorders. vii. The "a", or "b" or "c" or as "a+b", or "'a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling cholestasis disorders of any aetiology. viii. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling steatosis of liver and steatohepatitis disorders of any aetiology. ix. The "a", or "b" or "c" or as "a+b", or ''a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention, dissolution and controlling gall stone diseases. x. The "a", or "b" or "c"5 or as "a+b", or "a+c", or "b+c or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling all psychiatric and all neurologic diseases.
Claims (10)
1. All "a", "b" and "c" are effective if given as "a", or "b" or "c" or as "a+b", or ''a+c", or "b+c" or, "a+ b+ c".
2. All "a", "b" and "c" are effective if given as "a", or "b" or "'c"l or as "a+b" , or "a+c", or "b+c" or, "a+ b+ c" when provided in oral or parenteral, topical preparations.
3. All and any composition and any and all concentrations of "a", or "b" or "'c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" are effective.
4. Taurine used comes in its acid form or acid salt or alkali salt or in any of its compounds, forms or shapes.
5. The "a", or "b" or "'c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling astherselerosis and cardiac diseases. WO 2006/072259 PCT/EG2005/000044 5
6. The "a", or "b" or "c" or as "a+b", or ''a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling all hypercholestrolaemias, hypertriglycerdaemias, and all and any lipid and lipoprotein disorders.
7. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are .effective in prevention and controlling cholestasis disorders of any aetiology.
8. The "a", or "b" or 6c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling steatosis of liver and steatohepatitis disorders of any aetiology.
9. The "a", or "b" or 4c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling gall stone diseases.
10. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling all psychiatric and all neurologic diseases.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EG2005010013 | 2005-01-05 | ||
| EG2005010013 | 2005-01-05 | ||
| PCT/EG2005/000044 WO2006072259A2 (en) | 2005-01-05 | 2005-12-31 | Taurine synthesis, production and utility as a medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2005324199A1 true AU2005324199A1 (en) | 2006-07-13 |
Family
ID=36647837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005324199A Abandoned AU2005324199A1 (en) | 2005-01-05 | 2005-12-31 | Taurine synthesis, production and utility as a medicine |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1844006A2 (en) |
| JP (1) | JP2008526789A (en) |
| KR (1) | KR20070091198A (en) |
| CN (1) | CN101146767A (en) |
| AP (1) | AP2007004084A0 (en) |
| AU (1) | AU2005324199A1 (en) |
| BR (1) | BRPI0519606A2 (en) |
| CA (1) | CA2593563A1 (en) |
| EA (1) | EA200701434A1 (en) |
| IL (1) | IL184221A0 (en) |
| MA (1) | MA29238B1 (en) |
| MX (1) | MX2007008196A (en) |
| NO (1) | NO20074937A (en) |
| TN (1) | TNSN07226A1 (en) |
| WO (1) | WO2006072259A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5583022B2 (en) | 2007-11-30 | 2014-09-03 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | Method for treating non-alcoholic steatohepatitis (NASH) using cysteamine product |
| CN103382170B (en) * | 2012-10-25 | 2015-04-08 | 潜江永安药业股份有限公司 | Preparation method for taurine |
| CN106728405A (en) * | 2016-11-15 | 2017-05-31 | 陈思文 | A kind of taurine and water soluble tea polyphenol compound and preparation method and application |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58140017A (en) * | 1981-12-22 | 1983-08-19 | Junichi Azuma | Remedy for cardiac insufficiency |
| JPH08208464A (en) * | 1994-12-02 | 1996-08-13 | Taisho Pharmaceut Co Ltd | Treatment and prevention drug for hyperlipidemia |
| US6184227B1 (en) * | 1995-07-21 | 2001-02-06 | Savvipharm Inc. | Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases |
| SE9601395D0 (en) * | 1996-04-12 | 1996-04-12 | Dieter Haeussinger | New therapeutic treatment 1 |
| GB9722361D0 (en) * | 1997-10-24 | 1997-12-17 | Pharma Nord Uk Ltd | Pharmaceutical formulation for treating liver disorders |
| NZ527924A (en) * | 1999-01-29 | 2005-01-28 | Mars Uk Ltd | Antioxidant compositions and methods for companion animals |
| WO2001026642A2 (en) * | 1999-10-08 | 2001-04-19 | Joyce Corinne Bechthold | Methods and compositions for treating neurobehavioral disorders |
| CN1340502A (en) * | 2000-06-30 | 2002-03-20 | 张永春 | Process for preparing taurine zinc |
| CN1268733C (en) * | 2004-07-20 | 2006-08-09 | 刘辉 | Taurine functional beer and its producing process |
-
2005
- 2005-12-31 MX MX2007008196A patent/MX2007008196A/en not_active Application Discontinuation
- 2005-12-31 WO PCT/EG2005/000044 patent/WO2006072259A2/en not_active Ceased
- 2005-12-31 CA CA002593563A patent/CA2593563A1/en not_active Abandoned
- 2005-12-31 EA EA200701434A patent/EA200701434A1/en unknown
- 2005-12-31 AP AP2007004084A patent/AP2007004084A0/en unknown
- 2005-12-31 BR BRPI0519606-0A patent/BRPI0519606A2/en not_active IP Right Cessation
- 2005-12-31 EP EP05818935A patent/EP1844006A2/en not_active Withdrawn
- 2005-12-31 JP JP2007549796A patent/JP2008526789A/en active Pending
- 2005-12-31 CN CNA2005800460663A patent/CN101146767A/en active Pending
- 2005-12-31 KR KR1020077016443A patent/KR20070091198A/en not_active Withdrawn
- 2005-12-31 AU AU2005324199A patent/AU2005324199A1/en not_active Abandoned
-
2007
- 2007-06-14 TN TNP2007000226A patent/TNSN07226A1/en unknown
- 2007-06-26 IL IL184221A patent/IL184221A0/en unknown
- 2007-07-26 MA MA30110A patent/MA29238B1/en unknown
- 2007-09-28 NO NO20074937A patent/NO20074937A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN07226A1 (en) | 2008-11-21 |
| JP2008526789A (en) | 2008-07-24 |
| NO20074937A (en) | 2007-09-28 |
| AP2007004084A0 (en) | 2007-08-31 |
| MA29238B1 (en) | 2008-02-01 |
| WO2006072259A3 (en) | 2007-10-04 |
| WO2006072259A2 (en) | 2006-07-13 |
| MX2007008196A (en) | 2008-02-22 |
| EP1844006A2 (en) | 2007-10-17 |
| CA2593563A1 (en) | 2006-07-13 |
| KR20070091198A (en) | 2007-09-07 |
| BRPI0519606A2 (en) | 2009-02-25 |
| CN101146767A (en) | 2008-03-19 |
| IL184221A0 (en) | 2008-12-29 |
| EA200701434A1 (en) | 2008-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4533415B2 (en) | Cosmetic composition | |
| CN101098879B (en) | Novel Selenic Acids and Derivatives and Applications in Nutraceuticals, Cosmetics and Pharmaceuticals | |
| JPH07501539A (en) | Organic salt of N,N'-diacetylcystine | |
| EP0291245B1 (en) | Benzoylaminophenoxybutanoic acid derivatives | |
| EP0951909B1 (en) | Combination composition comprising a L-carnitine or an alkanoyl-L-carnitine, a glycosaminoglycan and/or constituent thereof | |
| JP2014185163A (en) | Therapies for cancer using isotopically substituted lysine | |
| KR20120084718A (en) | Collagen production accelerating composition | |
| EP0631779A1 (en) | Use of esters of L-carnitine and acyl L-carnitine with hydroxyacids for producing pharmaceutical compositions for treating dermatoses | |
| JP2002533421A (en) | Disease treatment using NAALADase inhibitor | |
| AU2005324199A1 (en) | Taurine synthesis, production and utility as a medicine | |
| JP5671483B2 (en) | Pigmentation preventing or improving agent | |
| EP4678629A1 (en) | Ionizable lipid molecule, preparation method therefor and use thereof | |
| WO2011074643A1 (en) | Prophylactic or ameliorating agent fo pigmentation | |
| FR2989087A1 (en) | NOVEL OLIGOSACCHARIDE COMPOUNDS AND THEIR COSMETIC USE | |
| HU229161B1 (en) | Lipophilic diesters of chelating agents | |
| JP7073384B2 (en) | Compounds and usage | |
| AU2024208147A1 (en) | Amino lipid compound, and preparation method therefor and use thereof | |
| WO2011030727A1 (en) | External preparation containing pantethine phosphate ester | |
| EP2072494B1 (en) | Cosmetic and pharmaceutical compositions | |
| CN109320577B (en) | Fusidic acid derivative with antitumor activity and synthesis and preparation method thereof | |
| EP1234816A1 (en) | Scyphostatin analogues as SMase inhibitors | |
| KR20030003952A (en) | Compositions for the prevention and treatment of inflammatory skin diseases | |
| CN105102466B (en) | The sugared dendroid cluster compound of inhibitor as BACE-1 | |
| EP1655281B1 (en) | Salts of N-acyl-L-aspartate-beta-mono-ester and/or of N-acyl-L-glutamate-gamma-monoester, the process for preparing them and their use in therapeutic or cosmetic compositions | |
| CN1251573A (en) | Solid composition suitable for oral administration comprising non hydroscopic salts of L-carnitine or alkanoyl-L-carnitine with 2-aminoethanesulfonic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |